Gujarat Themis Biosyn: Promoter Sachin Patel to Acquire Up to 0.50% Stake via Inter-se Transfer
Promoter Sachin D. Patel plans to acquire up to 0.50% stake (5,25,000 shares) in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group (India) Limited. The transaction, valued at up to ₹20 Crores, will occur between July 8-14, 2026, at ₹395.75 per share. This is an inter-se transfer among promoters.
The proposed acquisition represents a minor change in shareholding (up to 0.50%) among existing promoters and is unlikely to have a significant impact on the company's operations or market valuation.
The announcement pertains to an inter-se transfer of shares between promoters, which is a routine corporate action and does not inherently indicate a positive or negative development for the company's overall performance.
Gujarat Themis Biosyn Limited has announced an inter-se transfer of equity shares between promoters. Sachin D. Patel, a promoter, proposes to acquire up to 5,25,000 equity shares, representing up to 0.50% of the total share capital, from Pharmaceutical Business Group (India) Limited. The acquisition is planned between July 8, 2026, and July 14, 2026, at a price of ₹395.75 per equity share. The total value of the proposed acquisition is up to ₹20 Crores.
This transaction is an inter-se transfer among the Promoter and Promoter Group and is being conducted in compliance with Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquirer, Sachin D. Patel, has declared that the acquisition price will not exceed the stipulated limits and that all disclosure requirements under the Takeover Regulations have been or will be complied with. The acquisition is exempted from making an open offer under Regulation 10(1)(a)(ii) of the SEBI (SAST) Regulations.
Following the proposed transaction, Sachin D. Patel's shareholding (including persons acting in concert) is expected to increase from 2.29% to 2.77%, while the shareholding of Themis Medicare Limited, the seller, will decrease from 47.02% to 46.54%.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.